Events

Event When
Half-Year 2020 Financial Results reporting* July 23, 2020
Nine-months 2020 Financial Results reporting* October 22, 2020
Full year 2020 Financial Results reporting* February 4, 2021

*We will be in a silent period for 10 days ahead of the financial reporting.

First pivotal results with daridorexant for insomnia

In April 2020, Idorsia announced positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia.

 

First pivotal results with daridorexant for insomnia

Full Year 2019 Financial Results

Idorsia published its full year financial results 2019 on Thursday February 6, 2020.

Full Year 2019 Financial Results

Half Year 2019 Financial Results

Idorsia published its half year financial results 2019 on Tuesday July 23, 2019.

Half Year 2019 Financial Results

Full Year 2018 Financial Results

Idorsia published its full year financial results 2018 on Thursday February 7, 2019.

 

Full Year 2018 Financial Results

Phase 3 initiation: Aprocitentan for resistant hypertension management

In June 2018, Idorsia announced that the first patient had been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.

 

Phase 3 initiation: Aprocitentan for resistant hypertension management

Phase 3 Advancing: Clazosentan for cerebral vasospasm

In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.

 

Phase 3 Advancing: Clazosentan for cerebral vasospasm

Phase 3 initiation: Lucerastat for Fabry disease

In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.

 

Phase 3 initiation: Lucerastat for Fabry disease

Disclaimer

The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.

Contact

Investor Relations
Hegenheimermattweg 91
4123 Allschwil
Switzerland

Stay informed

Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.